The human immunoglobulin is normal (Immunoglobulinum humanum normale)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Immunoglobulins

Included in the formulation
  • Gabriglobin (human immunoglobulin is normal)
    lyophilizate d / infusion 
    IVANOV REGIONAL STATION OF BLOOD TRANSFUSION     Russia
  • Gabriglobin-IgG
    solution d / infusion 
    IMMUNO-GEM, CJSC     Russia
  • Gamunex®-C
    solution d / infusion 
    Grifols Therapyutics Inc.     USA
  • IGVena
    solution d / infusion 
    Kedrion SpA     Italy
  • Imbioglobulin
    solution d / infusion 
    MICROGEN FGUP Scientific and Production Association     Russia
  • Immunovinin®
    lyophilizate in / in 
    MICROGEN FGUP Scientific and Production Association     Russia
  • Immunoglobulin Segardis
    solution d / infusion 
    SIGARDIS ENG, LLC     Russia
  • Immunoglobulin Sigurdis MT
    solution d / infusion 
    SIGARDIS ENG, LLC     Russia
  • The human immunoglobulin is normal
    solution w / m 
    TAMBOV REGIONAL STATION OF BLOOD TRANSFUSION     Russia
  • The human immunoglobulin is normal
    solution w / m 
    IVANOV REGIONAL STATION OF BLOOD TRANSFUSION     Russia
  • The human immunoglobulin is normal
    solution w / m 
    LIPETSK REGIONAL STATION OF BLOOD TRANSFUSION     Russia
  • The human immunoglobulin is normal
    solution w / m 
    SVERDLOVSK REGIONAL STATION OF BLOOD TRANSFUSION OF GBUZ SO     Russia
  • The human immunoglobulin is normal
    solution w / m 
    SANGVIS SEC №2 СО СОЗ     Russia
  • The human immunoglobulin is normal
    solution w / m 
    MICROGEN FGUP Scientific and Production Association     Russia
  • The human immunoglobulin is normal
    solution in / in 
    MICROGEN FGUP Scientific and Production Association     Russia
  • The human immunoglobulin is normal
    solution w / m 
    Vologda Regional Blood Transfusion Station No.1     Russia
  • The human immunoglobulin is normal
    solution d / infusion 
    Nizhny Novgorod Regional Blood Center. N. Ya. Klimova     Russia
  • The human immunoglobulin is normal
    solution w / m 
    SAMARA REGION OF TRANSFUSION OF BLOOD     Russia
  • The human immunoglobulin is normal
    solution w / m 
    Chelyabinsk Regional Blood Transfusion Station     Russia
  • Intraglobin
    solution d / infusion 
    Biotest Pharma GmbH     Germany
  • Intratect
    solution d / infusion 
    Biotest Pharma GmbH     Germany
  • Kiovig®
    solution d / infusion 
    Baxter AG     Austria
  • Octagam
    solution d / infusion 
    Octapharma Pharmaceuticals Productionsgesb.H.     Austria
  • Octagam® 10%
    solution d / infusion 
    Octapharma Pharmaceuticals Productionsgesb.H.     Austria
  • Privived
    solution d / infusion 
    CESEL Behring AG     Switzerland
  • Phlebogamma 5%
    solution d / infusion 
    Institute Grifols S.A.     Spain
    • Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):

    ONLS

    VED

    АТХ:

    J.06.B.A.02   Immunoglobulin normal human for intravenous administration

    Pharmacodynamics:

    Contains a wide range of antibodies, due to immunoglobulin G has a wide spectrum of opsonizing and neutralizing antibodies against bacteria, viruses and other pathogens. In patients with secondary or primary immunodeficiency, the deficiency of the class IgG, decreasing the risk of infection.

    Pharmacokinetics:

    After intravenous infusion, the bioavailability of the drug is 100%. The maximum concentration in the blood plasma is maintained for 21 days.

    Penetrates through the blood-brain and placental barriers, enters the breast milk.

    The half-life period is 21 days; in patients with primary hypogammaglobulinemia (agammaglobulinemia), the half-life period is 32 days.

    Indications:

    It is used to treat severe toxic forms of bacterial and viral infections, postoperative complications, accompanied by septicemia in children and adults. Used in the postoperative period for complications accompanied by bacteremia. As a substitution therapy is used in the primary and secondary state of immunodeficiency.

    ICD-10

    I.A30-A49.A41.9   Septicemia, unspecified

    I.B00-B09.B09   Viral infection characterized by skin and mucous membrane damage, unspecified

    I.B99   Other infectious diseases

    III.D80-D89.D84.9   Immunodeficiency, unspecified

    XXI.Z20-Z29.Z29.1   Prophylactic immunotherapy

    Contraindications:

    Individual intolerance.

    Carefully:

    Renal failure, heart failure, diabetes mellitus.

    Pregnancy and lactation:

    Recommendations for FDA - Category C. It is used in pregnancy and lactation only for life indications.

    Dosing and Administration:

    Use in children

    A single dose is 3-4 ml / kg of body weight. Introduced daily, intravenously drip at a rate of not more than 10 drops per minute for 3-5 days.

    Adults

    Intravenously drip with an initial speed of 15-20 drops per minute, after 15-20 minutes the rate increases to 30-40 drops per minute. The course of treatment is from 3 to 10 infusions with an interval of 24 to 72 hours.

    The highest daily dose: 50 ml.

    The highest single dose: 50 ml.

    Side effects:

    Central and peripheral nervous system: headache, dizziness, rarely - hallucinations.

    The cardiovascular system: tachycardia, arterial hypotension, cyanosis, dyspnea, chest pain, tides, chills.

    Digestive system: abdominal pain, diarrhea.

    Musculoskeletal system: myalgia.

    Dermatological reactions: Hyperhidrosis.

    Allergic reactions.

    Overdose:

    Cases of overdose are not described.

    Treatment is symptomatic.

    Interaction:

    Immunoglobulin should not be mixed in the same volume with any other medicines.

    It is not used concomitantly with calcium gluconate in infants.

    Reduces the effectiveness of active immunization against rubella, chicken pox, measles, mumps. It is recommended to use antiviral vaccines 3 months after the application of immunoglobulin.

    Special instructions:

    After the introduction of immunoglobulin, a passive increase in the antibody content in the patient's blood is noted, which can lead to erroneous false positive interpretation of the results of serological testing.

    Instructions
    Up